Update Summary

Entity name

CHIMERIC THERAPEUTICS LIMITED

Announcement Type

Update to previous announcement

Date of this announcement

2/6/2023

Reason for update to a previous announcement

Close date changed to 16 June 2023 per announcement 2 June 2023.

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

CHIMERIC THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type	**Registration Number**
ABN	68638835828

1.3 ASX issuer code

CHM

1.4 The announcement is
☑ Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

Close date changed to 16 June 2023 per announcement 2 June 2023.

1.4b Date of previous announcement to this update

15/5/2023

1.5 Date of this announcement

2/6/2023

1.6 The Proposed issue is:
☑ An offer of +securities under a +securities purchase plan

Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?
☑ No

Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

CHM : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

CHM : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

131,250,000

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?
No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?
Yes

Describe the maximum subscription condition

Maximum $5,250,000 to be raised

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?
No

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?
Yes

Is the maximum acceptance unit based or dollar based?
Dollar based ($)

Please enter the maximum acceptance value

$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

to be described in SPP offer booklet

Offer price details

Has the offer price been determined?
☑ No

In what currency will the offer be made?

AUD - Australian Dollar

How and when will the offer price be determined?

The SPP is expected to be offered at a price the lesser of:
- $0.04 per share (13.0% discount to the last traded price and 24.9% discount to the 10-day VWAP)
- A 5% discount to the 5-day VWAP up to and including the closing date of the SPP

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?
☑ Yes

Describe the scale back arrangements

The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
☑ Yes

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

15/5/2023

4C.2 +Record date

12/5/2023

4C.3 Date on which offer documents will be made available to investors

22/5/2023

4C.4 Offer open date

22/5/2023

4C.5 Offer closing date

16/6/2023

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

23/6/2023

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?

☑ Yes

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

☑ Yes

4E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Bell Potter Lead Manager Fees:
- 3% management fee on proceeds of the SPP
- 4,500,000 advisor options

4E.2 Is the proposed offer to be underwritten?

☑ No

4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

☑ Yes

4E.3a Will the handling fee or commission be Dollar based or Percentage based?

☑ Percentage based (%)

4E.3b Amount of any handling fee or commission payable to brokers who lodge acceptances on behalf of investors

2.000000 %

4E.3c Please provide any other relevant information about the handling fee or commission method

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

The new funds will allow Chimeric to continue development of its world class portfolio of cell therapy programs.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

☑ No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

The SPP is open to eligible shareholders in Australia and New Zealand.

4F.3 URL on the entity's website where investors can download information about the proposed offer

https://chimerictherapeutics.com/investors/

4F.4 Any other information the entity wishes to provide about the proposed offer